(MedPage Today) — A phase III trial of investigational valiltramiprosate (ALZ-801) did not meet its primary endpoint in people with early symptomatic Alzheimer’s disease, but the drug did show benefits in a prespecified population with mild cognitive…
Source link : https://www.medpagetoday.com/meetingcoverage/ctad/118794
Author :
Publish date : 2025-12-02 19:26:00
Copyright for syndicated content belongs to the linked Source.
